Firefly Neuroscience (AIFF) Stock Price, News & Analysis

Company Overview

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function. In select studies, Firefly has incorporated lightweight sensor headbands to record electroencephalogram (EEG) signals, enhancing its ability to derive neurophysiological biomarkers. These digital measures are intended both for clinical trial sponsors evaluating investigational treatments and for healthcare providers seeking earlier intervention strategies.

Founded in 2017 and headquartered in the Greater Boston area, Firefly Neuroscience initially focused on Alzheimer’s disease and other forms of age‐related cognitive decline. The company collaborates with academic research centers, pharmaceutical partners and patient advocacy organizations to validate its tools across diverse populations. While its early clinical programs have been U.S.‐based, Firefly has signaled plans to expand its research partnerships and regulatory engagement in Europe and Asia.

Firefly Neuroscience is led by a management team with backgrounds in neuroscience, medical device development and digital health innovation. Through its integrated hardware-software approach, the company seeks to redefine how brain health is assessed, moving beyond episodic, clinic-based testing to continuous, data-driven insights that can accelerate drug development and enhance patient care.

Key Stats

• Today's Range: $1.68 to $1.82
• 50-Day Range: $1.50 to $3.02
• 52-Week Range: $0.62 to $3.77
• Volume: 184,086 shs
• Average Volume: 6.51 million shs
• Market Capitalization: $28.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Firefly Neuroscience Stock Analysis - MarketRank™

Firefly Neuroscience scored higher than 16% of companies evaluated by MarketBeat, and ranked 283rd out of 300 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Firefly Neuroscience has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Firefly Neuroscience has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Firefly Neuroscience is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Firefly Neuroscience is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Firefly Neuroscience has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.27% of the float of Firefly Neuroscience has been sold short.

Short Interest Ratio / Days to Cover

Firefly Neuroscience has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Firefly Neuroscience has recently decreased by 10.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Firefly Neuroscience does not currently pay a dividend.

Dividend Growth

Firefly Neuroscience does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: N/A

News Sentiment

Firefly Neuroscience has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Business Services companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Firefly Neuroscience this week, compared to 1 article on an average week.

Search Interest

4 people have searched for AIFF on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Firefly Neuroscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.44% of the stock of Firefly Neuroscience is held by insiders.

Percentage Held by Institutions

4.96% of the stock of Firefly Neuroscience is held by institutions.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/28/2026
• Next Earnings (Estimated): 6/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Business Services
• Industry: Technology Services
• Sub-Industry: Computer Software
• Current Symbol: NASDAQ:AIFF
• Previous Symbol: NASDAQ:AIFF
• CIK: 803578
• Web: fireflyneuro.com
• Phone: (888) 237-6412
• Fax: 703-293-7979
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.88 million
• Net Margins: -565.40%
• Pretax Margin: -565.09%
• Return on Equity: -94.68%
• Return on Assets: -73.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.82
• Quick Ratio: 1.78

Sales & Book Value

• Annual Sales: $1.14 million
• Price / Sales: 24.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.54 per share
• Price / Book: 3.33

Miscellaneous

• Outstanding Shares: 15,570,000
• Free Float: 14,569,000
• Market Cap: $28.03 million
• Optionable: N/A
• Beta: 0.60